Oragenics has signed a Letter of Intent to license CardioDialysis technology from Sigyn Therapeutics to target traumatic brain injury-induced systemic inflammation. The proposed license agreement would position Oragenics as the only company with therapeutic strategies targeting TBI-induced inflammation on both sides of the blood-brain barrier.
Overview
The CardioDialysis technology is an extracorporeal blood purification technology engineered to enable broad-spectrum clearance of inflammatory cytokines, endotoxins, and other pathogenic molecules from the bloodstream. Oragenics is currently advancing ONP-002, a first-in-class intranasal neurosteroid in Phase IIa clinical trials for concussion and mild traumatic brain injury.
What it does
The combination of ONP-002 and CardioDialysis would represent a dual-modality strategy designed to attack the inflammatory cascade of TBI at both the central and peripheral levels simultaneously. There are currently no FDA-approved pharmacological treatments for concussion or mild traumatic brain injury. Oragenics believes this multi-pronged approach could represent a significant advancement in the standard of care for the estimated 69 million individuals worldwide who suffer a brain injury each year.
Tradeoffs
The proposed transaction is structured as an exclusive, assignable license of the CardioDialysis technology for use in the agreed Target Markets. Key terms of the LOI include consideration, royalty, target closing, and exclusivity. The completion of a definitive agreement remains subject to due diligence satisfactory to Oragenics, board approvals by both companies, NYSE American continued listing compliance, and other customary closing conditions.
In practical terms, the licensing of CardioDialysis technology by Oragenics could lead to the development of more effective treatments for traumatic brain injury-induced systemic inflammation. As the only company with therapeutic strategies targeting TBI-induced inflammation on both sides of the blood-brain barrier, Oragenics is well-positioned to make a significant impact in this area.